Syros Pharma bails on cancer candidate SY-1365

Citing the greater anti-tumor activity of CDK7 inhibitor SY-5609 and its more flexible oral route of administration, Syros Pharmaceuticals (SYRS -27.5%) has decided to terminate development of intravenously administered CDK7 inhibitor SY-1365. A Phase 1 study should launch next quarter.

Investors appear to be reacting to the abrupt switch and longer timeline since the company was supposed to release data from a Phase 1 trial of SY-1365 this quarter.

https://seekingalpha.com/news/3506555-syros-pharma-bails-cancer-candidate-syminus-1365-shares-28-percent